Patient-specific Microstructural and radIobiological model for persoNalised external beam radiatIONn therapy in localised tumourS

External-beam radiotherapy has been established as best practice care in different cancer cases, although current models applied in the clinics to tune the treatment plan dosimetry, as a function of the expected tumour response and radiation-induced toxicity, do not make use of patient-specific information, but rely on radiobiological parameters typically derived from in-vitro experiments, thus abdicating from describing the in-vivo complexity of the pathology.

MINIONS is a cutting-edge research programme that investigates and integrates a set of activities to implement patient-specific microstructural and radiobiological models in personalized radiotherapy treatment planning and adaptation towards a detailed description of tumour characteristics of each patient and thus significantly improved tumour control probability.

The main challenge of MINIONS is to create, for the first time, a real-time patient-specific model able to describe the microscopic characteristic of the tumour and its interaction with the radiation beam.

The scientific activities of MINIONS are to achieve and merge: (i) Monte-Carlo (MC) simulations of Diffusion Magnetic Resonance (DW-MR) signals and radiation-tissue interactions on a library of in-silico cellular substrates to obtain an integrated simulation platform; (ii) real-time Artificial Intelligence-based techniques to accelerate MC simulations and make them compatible with fast treatment planning and adaptation; (ii) advanced DW-MR imaging, to retrieve non-invasively the information required to feed the simulation platform for the implementation of patient-specific microstructural and radiobiological models.

The design of in-vivo and ex-vivo tests allows validating the model performance and the collaboration of researchers, engineers and clinicians will drive the use of this innovative strategy in clinical routine, to increase survival and quality of life for a wide range of cancer patients.